Clinical characteristics of sarcoma patients: a population-based data analysis from a German clinical cancer registry.
Cancer registry
Overall survival
Prognostic factors
Progression-free survival
Soft tisse sarcoma
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
01
08
2023
accepted:
25
08
2023
medline:
27
11
2023
pubmed:
26
9
2023
entrez:
26
9
2023
Statut:
ppublish
Résumé
Sarcomas are a heterogeneous group of malignant neoplasms with a wide range of histological types and occur in almost any anatomic site and side. This study evaluated the prognostic factors in sarcoma patients based on German clinical cancer registry data. The German clinical cancer register of Saxony-Anhalt was used for all data analyses. Sarcoma cases of all clinical or pathological T-stages (T1a-T4c), all N-stages (N0-3) and M-stages (0-1b) corresponding to the Union for International Cancer Control (UICC) stages I to IVB were considered. In our analyses, 787 cases diagnosed between 2005 and 2022 were included. Further, we assessed the association of cancer-related parameters with mortality and hazard ratios (HR) from the Cox proportional hazard models. We included sex, age at diagnosis, histological grade, T-, N- and M-stages, tumor size, tumor localization and tumor side as parameters in our regression models. The majority of sarcoma patients were diagnosed with leiomyosarcoma (12%), liposarcoma (11%), angiosarcoma (5.3%) and myxofibrosarcoma (2.7%). In our univariate regression models, tumors localized in more than one location, head, face and neck region as well as the pelvis and lower extremity were associated with increased mortality risk (more than one location: HR 7.10, 95% CI 2.20-22.9; head, face and neck: HR 1.35, 95% CI 0.89-2.06; pelvis: HR 1.27, 95% CI 0.86-1.89; lower extremity: HR 1.44, 95% CI 1.05-1.96). Higher histological grades, UICC-grades and TNM-stages were related to a higher mortality risk. Differing histological subtypes had significant influence on overall survival and progression-free survival. Patients diagnosed with fibromyxoid sarcoma, rhabdomyosarcoma and angiosarcoma were related to higher mortality risk compared to other histological subtypes (fibromyxoid sarcoma: HR 5.2, 95% CI 0.71-38.1; rhabdomyosarcoma: HR 2.93, 95% CI 1.44-6.00; angiosarcoma: HR 1.07, 95% CI 0.53-2.18). Histological grade, tumor size, nodal and distant metastasis, tumor localization and histological subtype were determined as prognostic factors in terms of survival.
Identifiants
pubmed: 37750956
doi: 10.1007/s00432-023-05350-5
pii: 10.1007/s00432-023-05350-5
pmc: PMC10657284
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17051-17069Informations de copyright
© 2023. The Author(s).
Références
J Natl Compr Canc Netw. 2018 Feb;16(2):144-152
pubmed: 29439175
Cancer. 2012 Aug 1;118(15):3758-65
pubmed: 22180344
J Clin Oncol. 1999 Sep;17(9):2772-80
pubmed: 10561352
Cancer. 2016 Apr 1;122(7):1017-28
pubmed: 26849082
Ann Surg. 1994 Feb;219(2):165-73
pubmed: 8129487
Clin Transl Oncol. 2020 Jun;22(6):860-869
pubmed: 31392646
J Surg Oncol. 2021 Sep;124(4):635-645
pubmed: 34091907
Orthop Surg. 2021 Feb;13(1):134-144
pubmed: 33305494
J Cancer Res Clin Oncol. 2022 May;148(5):1087-1095
pubmed: 35064816
Acta Oncol. 2014 Sep;53(9):1188-96
pubmed: 24588412
Jpn J Clin Oncol. 2021 Jul 1;51(7):1080-1087
pubmed: 33791777
Eur J Surg Oncol. 1991 Feb;17(1):71-80
pubmed: 1995362
Arch Surg. 1992 Nov;127(11):1285-9
pubmed: 1444788
J Adolesc Young Adult Oncol. 2018 Dec;7(6):681-687
pubmed: 30096005
J Cancer Res Ther. 2020 Jul-Sep;16(4):903-908
pubmed: 32930138
BMJ Open. 2020 Nov 23;10(11):e038799
pubmed: 33234628
Sarcoma. 2018 Apr 4;2018:5671926
pubmed: 29849478
Oncotarget. 2019 Mar 29;10(25):2462-2474
pubmed: 31069009
BMJ Open. 2021 Feb 26;11(2):e042742
pubmed: 33637543
J Surg Oncol. 2004 Feb;85(2):68-76
pubmed: 14755506
Ann Oncol. 2014 Sep;25(9):1854-1860
pubmed: 24914041
Cancer. 2010 Oct 1;116(19):4613-21
pubmed: 20572040
J Clin Oncol. 1996 Mar;14(3):859-68
pubmed: 8622034
Cancer. 2001 Jul 15;92(2):359-68
pubmed: 11466691
Med Sci (Basel). 2018 Mar 06;6(1):
pubmed: 29509716
Lancet. 2002 Jun 29;359(9325):2235-41
pubmed: 12103287
Clin Sarcoma Res. 2012 Oct 04;2(1):14
pubmed: 23036164
Acta Oncol. 2020 Feb;59(2):127-133
pubmed: 31702424
Eur J Cancer. 2013 Feb;49(3):684-95
pubmed: 23079473